76 results
8-K
EX-99.1
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its
8-K
EX-99.1
IMVT
Immunovant Inc
9 Jan 24
Regulation FD Disclosure
8:08am
such as the post-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chains
8-K
EX-99.1
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
, successfully commercialized; the potential impact of global factors, such as the post-COVID-19 environment, geopolitical tensions, and adverse macroeconomic
8-K
EX-99.1
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
, successfully commercialized; the potential impact of global factors, such as the post-COVID-19 environment, geopolitical tensions, and adverse
8-K
EX-99.2
4iyr4s81r5sx5aga
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
S-3ASR
EX-1.2
3siqj i18n
9 Nov 23
Automatic shelf registration
8:49am
S-3ASR
rvwn3 wexr4dppf
9 Nov 23
Automatic shelf registration
8:49am
8-K
EX-99.1
m6p4wf5
9 Nov 23
Results of Operations and Financial Condition
7:06am
424B5
tdrw2d11 s2a4b
29 Sep 23
Prospectus supplement for primary offering
4:48pm
8-K
EX-1.1
n0dfujwo5c7e5c81dbg
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
424B5
npytvh4qssfsg
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
kp1y7 39uoh
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
EX-99.1
xb94cgqpvphietqz6
10 Aug 23
Results of Operations and Financial Condition
7:10am
424B5
tjq kj51iv0tr
5 Oct 22
Prospectus supplement for primary offering
4:43pm
8-K
EX-1.1
rmxr0l99
4 Oct 22
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
5:28pm